National Cancer Institute Signs an Agreement with Celera Genomics
Rockville, MD - July 09, 2001
Celera Genomics (NYSE: CRA), an Applera Corporation business, announced it signed a memorandum of understanding with the National Cancer Institute (NCI) of the National Institutes of Health (NIH). The memorandum of understanding outlines the terms and conditions under which individual NCI principal investigators may elect whether or not to purchase access to Celera’s analytical tools and database products, including the fruit fly, human, and mouse genomes. The subscribers will access Celera's database information through the Celera Discovery System.
The Celera Discovery System is an integrated, web-based platform that enables users to leverage Celera’s computational tools, super-computing power, and genomic and biological data to advance the discovery process for researchers worldwide.
Applera Corporation, formerly PE Corporation, comprises two operating groups. The Celera Genomics Group, headquartered in Rockville, MD, intends to be a definitive source of genomic and related medical information. Celera has developed three business units: the On-line Information Business, Discovery Sciences, and Discovery Services, all of which build upon Celera’s generation, integration, and analysis of biological information. Celera intends to enable therapeutic discoveries both through its own application of its scientific capabilities and in partnership with pharmaceutical and biotechnology companies. The Applied Biosystems Group (NYSE:ABI) develops and markets instrument-based systems, reagents, software, and contract services to the life science industry and research community. Applied Biosystems is headquartered in Foster City, CA, and reported sales of $1.4 billion during fiscal 2000. Information about Applera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available on the World Wide Web at www.applera.com, or by telephoning 800.762.6923.
Certain statements in this press release are forward-looking. These may be identified by the use of forward-looking words or phrases such as “believe,” “expect,” “anticipate,” and “potential,” among others. These forward-looking statements are based on Applera Corporation’s current expectations. The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for such forward-looking statements. In order to comply with the terms of the safe harbor, Applera Corporation notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in forward-looking statements within this press release. The risks and uncertainties include but are not limited to: (1) dependence on the final assembly and annotation of the human genome; (2) unproven use of genomics information to develop products; (3) dependence on computer hardware, software, and internet applications; (4 ) potential adverse effect on the Celera Genomics group’s intellectual property protection and the value of its products and services due to public disclosure of genomics sequence data; (5) government regulation of Celera’s products and services; and (6) other factors that might be described from time to time in Applera Corporation’s filings with the Securities and Exchange Commission.
Notice To Readers: Celera's press releases, presentations and printed remarks are included on this website for historical purposes only. The information contained in these documents should be considered accurate only as of the date of the relevant document. This information may change over time, and therefore visitors to this website should not assume that the information contained in these documents remains accurate at a later time. We do not have any current intention to update any of the information in these documents.